4Filed Aug 5, 8:00 PM ET

Enliven (ELVN) Director Derynck Mika K Exercises Options, Sells Shares

$ELVN · Enliven Therapeutics, Inc.

Research Summary

AI-generated summary of this SEC filing

Updated

Enliven (ELVN) Director Derynck Mika K Exercises Options, Sells Shares

What Happened

  • Director Derynck Mika K exercised multiple option tranches and sold shares on August 4, 2026. The filing shows exercises of 87,373; 27,567; 23,364; and 20,491 option shares at exercise prices of $2.48, $25.28, $14.85, and $22.47 respectively (cash paid shown). Separately, 158,795 shares were sold in the open market at a weighted average price of $60.21, generating proceeds of approximately $9,561,587.

Key Details

  • Transaction date: 2026-08-04; Form 4 filed: 2026-08-06 (filed within standard reporting window).
  • Sales: 158,795 shares sold in multiple trades at prices from $60.00 to $60.58; weighted average $60.21; proceeds ≈ $9.56M. (Footnote F2)
  • Option exercises: total exercised across four tranches = 158,695 shares (87,373 + 27,567 + 23,364 + 20,491) at stated exercise prices ($2.48, $25.28, $14.85, $22.47) with the corresponding cash amounts shown in the filing.
  • Derivative disposals reported at $0.00 indicate shares related to the option transactions were also recorded as derivative dispositions in the filing (see footnotes). (Transaction code M = option exercise; S = sale.)
  • Footnotes: F1 – transactions were executed under a Rule 10b5‑1 trading plan adopted April 8, 2025. F3 – all option shares were fully vested and exercisable as of the date of exercise.
  • Shares owned after transaction: not specified in the provided summary of the Form 4; refer to the full filing for the post-transaction beneficial ownership number.

Context

  • This was an option exercise combined with an open‑market sale. The presence of a 10b5‑1 plan (F1) indicates the sales were executed according to a pre‑arranged trading plan rather than ad hoc market timing.
  • The filing structure (exercises plus an immediate open‑market sale) is consistent with typical cash exercise and subsequent sale or with shares used to cover exercise/tax obligations; the Form 4 shows separate exercise acquisitions and market sale(s).
  • No indication of late filing in the provided data; the Form 4 was filed two days after the transactions, which is within the usual insider-reporting window.